BactPac™
Disrupting drug delivery
A quick look at the BactPac delivery platform
The BactPac delivery platform
SiVEC’s BactPac delivery platform is built on a highly and carefully engineered bacterial strain that provides a safe and complete solution for both production and delivery of nucleic acid, protein, and gene therapy cargo.
How does BactPac work?
BactPac uses normal flora bacteria engineered to 1) produce therapeutic nucleic acids, proteins, and gene editors, 2) deliver these therapeutic payloads to targeted tissues, and 3) release the payload into the targeted cell.
SiVEC Biotechnologies holds expertise and intellectual property (IP) for BactPac, a platform technology that can be applied to target a wide range of diseases in humans and animals. Efforts are focused on broadening our bacterial platform’s applications, with an emphasis on ensuring strong IP protection.
A deeper dive into BactPac
Introduction
SiVEC Biotechnologies has developed BactPac, a live biotherapeutic delivery platform to enable the next generation of nucleic acid and gene editing therapies. Nucleic acids have remarkable potential as therapeutic candidates, but development efforts often stall during early preclinical development due to lack of safe and tissue-targeted delivery, creating a large unmet need for delivery systems that enable the full potential of these next-generation therapies. SiVEC’s BactPac platform is set to meet these needs head on. Our specialized bacteria are engineered to safely deliver therapeutic payloads (mRNA, siRNA, proteins/nanobodies, and CRISPR/Cas systems) anywhere in the body.
The BactPac Platform
SiVEC’s BactPac delivery platform is built on a highly and carefully engineered bacterial strain that provides a safe and complete solution for both production and delivery of therapeutic cargo. We have demonstrated remarkable versatility in the types of cargo BactPac can make and deliver, including siRNA, mRNA, CRISPR/Cas, and proteins. The BactPac vehicles can generate large and varied therapeutic moieties that have applications in a wide range of indications, including cancer as well as genetic, infectious, and chronic diseases. The BactPac platform is enabling the company's own internal first-in-class pipeline, and serves as an adaptable tool for biopharma partners, enabling them to develop their own therapeutic pipelines. Therefore, the BactPac delivery platform is quite versatile and has wide market potential.
First-in-class Therapeutic Pipeline
First-in-class therapeutic pipeline: 1) SVC-KRAb™: a pan-KRAS-inhibiting therapy for mutant KRAS-driven cancer (pancreatic and lung) (in pre-clinical development); 2) SiVEC-IAV™: an influenza-targeting siRNA therapeutic delivered to the lungs; a cocktail of two siRNAs targeting conserved regions of influenza viral genes, providing fast-acting broad anti-influenza activity against seasonal and pandemic flu. SiVEC-IAV is in IND enabling studies and is sponsored by NIH/NIAID.
Value for Partners
SiVEC’s delivery system is extremely versatile. Partners can use the BactPac platform as a tool to build their own therapeutic pipelines for distinct disease indications using a variety of therapeutic approaches.
SiVEC seeks collaborations or partnerships from large, mid, and small biotech companies who are interested in evaluating the BactPac platform to enable the delivery of specific nucleic acid drugs (mRNA, siRNA, ASOs), polypeptide drugs (antibodies, nanobodies, proteins), or gene-editors (CRISPR, TALENS, etc.) to specific sites in the body (e.g., pancreas, lung, brain, heart).